Page last updated: 2024-08-21

erythromycin and Hematologic Neoplasms

erythromycin has been researched along with Hematologic Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chauhan, V; Córdoba, R; de Jong, J; De Wilde, S; de Zwart, L; Hellemans, P; Jiao, J; Manikhas, G; Masterson, T; Myasnikov, A; Osmanov, D; Ouellet, D; Panizo, C; Patricia, D; Snoeys, J; Sukbuntherng, J	1

Trials

1 trial(s) available for erythromycin and Hematologic Neoplasms

Article	Year
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies. Leukemia & lymphoma, 2018, Volume: 59, Issue:12 Topics: Adenine; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erythromycin; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Piperidines; Polymorphism, Single Nucleotide; Pyrazoles; Pyrimidines; Voriconazole	2018

Article

Year

A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.

Leukemia & lymphoma, 2018, Volume: 59, Issue:12

Topics: Adenine; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erythromycin; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Piperidines; Polymorphism, Single Nucleotide; Pyrazoles; Pyrimidines; Voriconazole

2018